To develop the skills of making the new marketing strategies for a product and to ensure the appropriate selling price of drug in the market and to distinguish the difference in the price of same drug from different brands, and to compare them with the DPCO prices.

1. COMPARATIVE STUDY ON THE
BASIS OF DPCO ON EXISTING
MARKETING STRATEGIES FOR
DIFFERENT DRUGS

2. CONTENTS
 Rationale
 Introduction
 Drug name
 Price as per DPCO.

3. RATIONALE
To develop the skills of making the new marketing
strategies for a product and to ensure the appropriate
selling price of drug in the market and to distinguish the
difference in the price of same drug from different brands,
and to compare them with the DPCO prices.

4. INTRODUCTION
DPCO is an order issued by the government under the
Essential Commodities Act, which enables it to fix the price
of some essential bulk drugs and their formulations. The
origin of this control dates back to 1970 when for the first
time government placed limit on profitability of
pharmaceutical companies.

5. S.No. Brand name Company
name
MRP
(in Rs)
1. Okavir DT 200mg Cipla 3.40
2. Docvir DT 200mg Mankind 5.20
3. Herperax Tab
200mg
Micro Gratia 8.4
4. Cyclovir 200mg Cadila
Healthcare
19.50
Drug name- Acyclovir
Price as per DPCO- Rs.8.06

6. S.No. Brand name Compay
name
MRP
(in Rs)
1. Efavir 200mg Cipla 26.90
2. Estiva 200mg Hetero HC 34.00
3. Efcure 200mg Emcure 25.97
4. Evirenz 200mg Alkem 27.00
Drug name- Efavirenz
Price as per DPCO- Rs.25.57

7. S.No. Brand name Company
name
MRP
(in Rs)
1. Glumet 500mg Cipla 0.65
2. Insumet 500mg Cadila 0.86
3. Metlife 500mg Mankind 0.60
4. Gluformin-XL
500mg
AHPL 2.10
Drug name- Metformin
Price as per DPCO-Rs. 1.72

8. Cipla was born out of Dr. K.A. Hamied’s vision to harness Indian
expertise for self-sufficiency in the chemical and pharmaceutical
industry in India. the landmark Indian Patents Act of 1970, the
several ‘firsts’ in India and the world, its historic international
stance on the price and availability of antiretroviral drugs for HIV
treatment in 2000-2001.
TURNOVER - RS. 4,000 CRORE
CIPLA

9. Mankind Pharma, one of the top 5 leading pharmaceutical companies in
India, started its journey in 1995. Provide a wide range of products –
Antibiotic, Antifungal, NSAIDs, Gastrointestinal, Anthelmintic,
Cardiovascular, Dermal, Erectile Dysfunction, and several other
categories – across the nation.
TURNOVER - RS. 3,400 CRORE
MANKIND

10. Cadila was founded in 1952 by Ramanbhai Patel (1952–2001).It evolved
over the next four decades into an established pharmaceutical
company. In 2015 the company acquired another Indian pharmaceutical
company called German Remedies. On June 25, 2007, the company
acquired Quimica e Farmaceutica Nikkho do Brasil Ltd (Nikkho) as part
of Zydus Healthcare Brasil Ltd.
TURNOVER – RS.1944 MIILIONS
ZYDUS CADILA

12. REFERENCES
• http://www.drugsupdate.com/brand/showavailablebrands/13
• http://www.drugsupdate.com/brand/showavailablebrands/44
• http://www.drugsupdate.com/brand/showavailablebrands/298